Background: Laboratory evidences suggest the possibility that an infusion rate of 10 mg/m 2 /min may be more effective than the standard 30-min infusion of Gemcitabine (GEM).
Introduction
Pancreatic cancer is a rapidly fatal disease, with a fiveyear survival rate of less than 5% [1] . Until very recently, chemotherapy was held to be largely ineffective in terms of objective response, survival or quality of life in advanced pancreatic cancer [2] . However, in the last years, opinions about the value of chemotherapy in advanced pancreatic cancer are changing. Cautious optimism for systemic chemotherapy is growing. This has been prompted by new drugs and new treatment end points as quality of life and symptom palliation. In fact, recent clinical trials with new drugs that have included analysis of clinical benefit have confirmed that chemotherapy is worthwhile and it can represent an important tool for improving the patient conditions [3] .
Gemcitabine (GEM), a novel nucleoside analogue, is the most investigated new drug in pancreatic cancer [4] . It showed a very favourable toxicity prophile and demonstrated activity in advanced pancreatic cancer, also reducing symptoms caused by the cancer [5] .
The 30-min infusion of GEM has become the standard administration schedule. However, laboratory evidences suggest the possibility that an infusion rate of 10 mg/m 2 /min may be more effective [6] . In fact, maximal intracellular levels of difluorodeoxycitidine trisphosphate, the principle active metabolite of GEM, is generated at sustained plasma gemcitabine concentrations of 15-20 umol/1. Such levels can be maintained for a longer period of time by administering the drug at the constant dose rate of 10 mg/m 2 /min [6] . Furthermore, these preclinical findings seemed to be confirmed clinically by the preliminary results of a randomized phase II trial comparing the two modalities of GEM infusion [7] .
Recently, we have shown that a standard 30-min infusion of GEM and 5-FU combination is feasible and active in the treatment of advanced pancreatic cancer patients. In fact, while response rate is substantially similar to that achievable with GEM alone, clinical benefit was obtained in about 50% of patients, without any worsening of GEM toxicity [8] .
Building on the possible advantages of a GEM fixed dose rate infusion, we modified our GEM /5-FU schedule giving GEM by an infusion rate of 10 gm/m 2 /min at the dose of 1,500 mg/m 2 as suggested by a phase I trial [9] .
Patients and methods
Patients with histologically verified locally advanced unresectable and/ or metastatic pancreatic carcinoma were eligible for the study. Other elegibility criteria included measurable disease, Karnofsky performance status (KPS) 100-60, age less 70 years, normal liver, renal and bone marrow functions, and no prior chemotherapy.
Informed consent was obtained from all participants after the nature of the study had been fully explained and the protocol was approved by the institutional review board.
GEM was diluted in normal saline and administered by an infusion rate of 10 mg/m 2 /min at the dose of 1,500 mg/m 2 by an intravenous infusional pump. 5-Fluorouracil (5-FU) was given as an i.v. bolus at the dose of 600 mg/m 2 . Both drugs were administered once weekly for two consecutive weeks out of every three weeks.
Treatment with GEM and 5-FU continued until there was evidence of disease progression or until there was significant clinical deterioration because of tumor-related symptoms.
Tumor response was classified according to WHO criteria and documented by two investigations at least six weeks apart [10] . Disease status for patients was assessed every six weeks. In addition to objective response, the clinical benefit measurement was assessed prospectively. It derived from measurament of three common debilitating signs or symptoms present in most patients with advanced pancreatic cancer: pain, functional impairment and weight loss [11] .
According to the optimal two-stage phase II study design, the treatment was designed to refuse response rate <20% (pO) and to provide a statistical power of 90% in assessing the activity of the regimen (in terms of response rate) as 35% (pi) (pl-pO = 15%) for an alpha error less than 0.05 [12] .
Results
Investigators from 8 GISCAD centres treated 34 advanced pancreatic cancer patients with this regimen for a total of 128 cycles of chemotherapy from October 1998 to December 1999. The characteristics of treated patients are detailed in Table 1 . All patients were evaluable for tumor response but only 29 for clinical benefit since 5 patients had a KPS of 100 and did not complain of pain.
Tumor response
All patients had measurable disease on computerized tomography scan at the study entry. One complete and five partial responses have been observed for an overall response rate of 17% (95% CI: 3%-27%). Eleven patients had a stable disease and 17 progressed on therapy. The time to progression was 3.7 months, with a median survival of 5.7 months. 
Clinical benefit
Five of twenty-nine patients (17%) were classified as positive in the pain category. In three patients both pain and KPS improved while in the other two there was an improvement in pain with no worsening of performance status. Therefore these patients were classified as clinical benefit responders by their primary measures. With regard to the secondary measure of clinical benefit, two patients had a positive weight change. All of them had already been categorized as clinical benefit responders by primary measures. The other three patients achieving a clinical benefit had a stable weight.
Toxicity
Side-effects were mainly represented by hematological toxicity ( Table 2) . Grade 3-4 WHO toxicities included neutropenia (35% of patients) and thrombocytopenia (10%). The dose of GEM was reduced in 12 patients (36%) and treatment was delayed in 11 patients (32%).
Discussion
In an our previous experience on the treatment of advanced pancreatic cancer with 5-FU (same schedule) and GEM (the standard 30-min infusion) we demonstrated that the association was feasible and well tolerated, reporting a low response rate (3.7%) similar to that obtained with GEM alone, but a higher rate (about 50%) of patients experiencing a clinical benefit [8] . Since the toxicity of the combination of GEM, given by standard 30-min infusion, and 5-FU was mild or absent in our experience, as well as in other studies [13] [14] [15] , we modified our regimen choosing a schedule of GEM reported to be more active both on laboratory evidence and in early clinical trials, even if probably more toxic, in order to improve the activity of this combination [6, 7] . In our opinion, although 5-FU could contribute to improve results, it was unlikely that a more intensive schedule of this drug was able to increase the overall activity of the combination. In fact, prolonged infusion or biochemical modulation by leucovorin of 5-FU associated with GEM did not seem to determine better results compared with our simpler schedule of weekly bolus 5-FU [13, 14] . Recently, an european trial seems to confirm this lack of [15] . In spite of the preclinical and clinical data, the results of the present study are clearly unsatisfactory. Although we registered a higher response rate (17%), clinical benefit was achieved in only 5 of 29 patients (17%). Also the median survival did not improve: 5.7 months versus 1 months obtained with a standard GEM infusional schedule.
Our results in terms of tumor response and survival compare well with data from Tempero et al. In 30 advanced pancreatic cancer patients treated with GEM (1,500 mg/m 2 ) alone at a rate of 10 mg/m 2 /min, they found a response rate of 16% and a median survival of 6 months [7] . They did not assess the clinical benefit but in our trial the disappointing results about this end point may be due to the interference of toxicity on the positive effects of chemotherapy. An increase in response rate does not necessarily translate in a better palliation of symptoms if a significant toxicity is associated, as demonstrated by the rate of patients (68%) unable to receive the planned schedule.
Based on these data, the addition of 5-FU to a fixed dose rate infusion of GEM can be questioned since response rate is substantially equivalent to those achievable with GEM alone [7] . Nevertheless, at least in our experience, it seems to be preferable a combination of standard GEM infusion with a bolus 5-FU considering toxicity and clinical benefit achievements.
In conclusion, our results in terms of clinical benefit, median survival and toxicity do not support an advantage for this schedule, and do not seem to suggest the opportunity of planning a randomized trial comparing fixed dose rate infusion, at least with this dose, with the standard 30-min infusion schedule in advanced pancreatic cancer.
